Table 4.
Analysis of characteristics of serious vs. non-serious DRESS syndrome cases
| Serious DRESS syndrome cases | Non-serious DRESS syndrome cases | OR (95% CI) | P value | |
|---|---|---|---|---|
| N | 1055 | 39 | ||
| Age, median (Q1–Q3) | 43.00 (29.0–55.00) | 38.5 (27.00–52.00) | NA | 0.31 |
| Sex, female, n (%) | 435 (42.36)a | 22 (57.89)b | 1.87 (0.93–3.86) | 0.07 |
| BMI, median (Q1–Q3) | 23.88 (21.25–28.43) | 24.17 (22.76–28.52) | NA | 0.77 |
| Dose (PDD/DDD), median (Q1–Q3) | 0.67 (0.18–1.30) | 0.50 (0.21–0.67) | NA | 0.38 |
| Duration of AP treatment (days), median (Q1–Q3) | 22.00 (12.00–46.00) | 16.00 (4.00–23.00) | NA | 0.10 |
| Duration of DRESS (days), median (Q1–Q3) | 11.00 (5.00–25.00) | 12.50 (6.00–13.75) | NA | 0.57 |
| Co-medication with anticonvulsants, n (%) | 416 (39.43) | 17 (43.59) | 0.84 (0.42–1.71) | 0.62 |
| Co-medication with antibiotics, n (%) | 55 (7.87) | 0 (0) | NA | 0.07 |
| Co-medication with miscellaneous, n (%) | 51 (4.83) | 0 (0) | NA | 0.25 |
| > 2 antipsychotics, n (%) | 245 (25.0) | 3 (8.6) | 3.56 (1.10–18.3) | 0.03 |
| Oral/LAIc | 577/18 | 16/2 | 3.99 (0.41–19.16) | 0.11 |
AP antipsychotic, BMI body mass index (kg/m2), CI confidence interval, DDD defined daily dose, DRESS drug reaction with eosinophilia and systemic symptoms, n number, LAI long-acting injectable, NA not applicable, OR odds ratio, PDD prescribed daily dose, Q1 first quartile, Q3 third quartile
aData available for 1027 cases
bData available for 38 cases
cAdministration route was reported otherwise or missing in 481 cases